Two new clinically effective melanoma vaccines exploit improvements in the way tumor antigens can be ‘presented’ to the immune system (pages 321–327 and 328–332).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Robbins, P.F. & Kawakami, Y. Human tumor antigens recognized by T cells. Curr Opinion in Immunol. 8, 628–636 (1996).
Marchand, M. et al. Tumor regression responses inmelanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63, 883–885 (1995).
Nestle, F.O. et al. Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells. Nature Med 4, 328–332 (1998).
Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4, 321–327 (1998).
Hart, D.N. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90, 3245–3287 (1997).
Schuler, G. & Steinman, R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 186, 1183–1187 (1997).
Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2, 52–58 (1996).
Bennett, S.R.M. et al. Induction of a CD8+ cytotoxic T cell response by cross-priming requires cognate CD4+ help. J Exp Med 186, 65–70 (1997).
Jaeger, E. et al. Generation of cytotoxic T-cell responses with synthetic melanoma associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66, 162–169 (1996).
Toes, R.E.M. et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to inability to reject tumors. J Immunol 156, 3911–3918 (1996).
Rosenberg, S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175–182 (1997).
Chouaib, S. et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18, 493–497 (1997).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Timmerman, J., Levy, R. Melanoma vaccines: Prim and proper presentation. Nat Med 4, 269–270 (1998). https://doi.org/10.1038/nm0398-269
Issue date:
DOI: https://doi.org/10.1038/nm0398-269
This article is cited by
-
An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
Cancer Immunology, Immunotherapy (2011)
